ArticleCureus2024
A Study of p63 Immunohistochemical Expression in Benign and Malignant Breast Lesions at a Tertiary Hospital in South India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Breast cancer is one of the leading causes of cancer deaths in female patients. Breast lesions can have various morphological diversities, ranging from benign to in situ to malignant. An important histopathological feature that distinguishes benign and malignant lesions is the presence or absence of the myoepithelial cell layer. The tumor protein p63 has been characterized as a reliable immunohistochemical marker and is uniquely displayed in the myoepithelial cells of breast parenchyma. Hence, it helps distinguish benign from malignant lesions. Aim To study the value of the immunohistochemical expression of p63 in the diagnosis of breast lesions, to investigate p63 expression in benign and malignant breast lesions, and to assess if loss of p63 expression is consistently associated with invasive disease. Materials and methods About 98 cases of breast disease were studied, of which 86 were subjected to immunohistochemical staining for p63 and analyzed for its expression, and the staining arrangement was interpreted. Results Out of 86 cases, there were 46 benign and 40 malignant breast lesions. Immunohistochemical staining for p63 in the benign lesions showed continuous positivity with a score of three in 30 cases and discontinuous positivity with a score of two in 16 cases. In malignant lesions, p63 was not expressed and scored zero in 35 cases and discontinuous positive with a score of one in five cases. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of p63 in distinguishing the benign from the malignant lesions was 100%, 87.50%, 90.20%, 100%, and 94.19% respectively. Conclusion There is a statistically significant difference in the expression of p63, a specific nuclear marker for myoepithelial cells, in benign and malignant breast lesions. It was consistently positive in benign breast lesions and negative in the majority of malignant breast lesions. Thus, p63 can act as a helpful immunohistochemical marker in categorizing histopathologically-difficult cases into benign or malignant ones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.